Which pharmaceutical company develops and produces Erdafitinib?

Erdafitinib (trade name: Balversa™) is a drug developed by Astex Pharmaceuticals and Janssen Pharmaceuticals (part of Johnson & Johnson) is an oral small molecule targeted drug jointly developed, which mainly targets the fibroblast growth factor receptor (FGFR), especially the FGFR1‑4 subtype.

Astex Pharmaceuticals Originated from Newcastle University in the UK, it is a biotechnology company focusing on the research and development of innovative drugs. As early as 2008, Astex signed a global exclusive license agreement with Janssen Astex will be responsible for the screening and optimization of the initial compounds, and then Janssen will take over the subsequent clinical development, registration application and commercial promotion.

Janssen (the pharmaceutical division of Johnson & Johnson), as the main force responsible for global clinical trials, regulatory approvals and sales, received the "Breakthrough Therapy Designation" (Breakthrough) from the U.S. FDA in April 2019. Therapy Designation), and obtained the FDAFDA on 4month12 of the same year. span>Officially approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who carry specific FGFR2 or FGFR3 gene alterations. In January of 2024, the US FDA further approved it as FGFR3 The treatment is provided for patients with positive locally advanced or metastatic urothelial carcinoma. The European Medicines Agency (EMA) also granted corresponding approval in August 2024.

From a pharmacological perspective, as the first FGFR inhibitor approved for this indication, Erdafitinib can block the FGFR-mediated tumor signaling pathway, inhibit tumor cell proliferation and induce apoptosis. Key clinical studies (such as BLC2001 and BLC3001/THOR Phase III studies) have shown that, Compared with standard chemotherapy, it has significantly improved progression-free survival (PFS) and overall survival (OS).

To sum up, erdafitinib is an FGFR targeted anti-tumor drug pioneered by Astex and led by Janssen for development and marketing. It has been successfully used in the treatment of urothelial cancer related to FGFR gene changes. Its R&D background reflects the collaborative model between biotech companies and large pharmaceutical companies and is a typical representative in the field of precision medicine and targeted therapy.

Reference link:https://www.balversa.com/